Synthetic: Regulation Fd Disclosure

The following excerpt is from the company's SEC filing.

Synthetic Biologics, Inc. (the “Company”) will be making several investor presentations over the next several of weeks. In connection with the presentations, the Company intends to discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein by reference.

The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as a mended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Synthetic Biologics makes a similar move, sign up!

Other recent filings from the company include the following:

Synthetic Biologics Just Filed Its Annual Report: Loss per Share ... - Feb. 20, 2020
Synthetic Biologics Reports 2019 Year End Operational Highlights And Financial Results - Feb. 20, 2020
Statement of acquisition of beneficial ownership by individuals - Feb. 14, 2020
Synthetic Biologics Announces Acceptance Of Compliance Plan By Nyse American - Feb. 7, 2020

Auto Refresh